$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000112534521000035 Filed on February 25, 2021

Income Statement

Concept	2019 Q4	2018	2017 Q4
Revenue	$25.19M	$60.12M	$152.4M
YoY Change	59.5%	-61.89%	2883.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.90M	$40.50M	$8.400M
YoY Change	13.33%	23.85%	-8.7%
% of Gross Profit
Research & Development	$52.00M	$190.8M	$39.00M
YoY Change	10.87%	29.61%	25.4%
% of Gross Profit
Depreciation & Amortization	$2.730M	$9.160M	$1.340M
YoY Change	-9.3%	26.73%	-32.32%
% of Gross Profit
Operating Expenses	$63.80M	$190.8M	$47.40M
YoY Change	10.96%	29.61%	17.62%
Operating Profit		-$171.2M
YoY Change		673.18%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$8.300M	-$247.0K	$800.0K
YoY Change	-376.67%	-109.81%	60.0%
Pretax Income	-$30.40M	-$171.5M	$105.7M
YoY Change	-31.84%	775.0%	-403.74%
Income Tax		$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$30.40M	-$171.5M	$105.7M
YoY Change	-31.91%	773.6%	-403.96%
Net Earnings / Revenue	-120.66%	-285.18%	69.39%
Basic Earnings Per Share			$2.87
Diluted Earnings Per Share	-$621.7K	-$4.193M	$2.80
COMMON SHARES
Basic Shares Outstanding	48.92M shares		36.82M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$215.8M	$232.9M	$305.1M
YoY Change	-7.34%	-23.66%	10.14%
Cash & Equivalents	$126.5M	$220.1M	$211.7M
Short-Term Investments	$89.30M	$12.70M	$93.40M
Other Short-Term Assets	$11.30M	$6.700M	$3.600M
YoY Change	68.66%	86.11%	-14.29%
Inventory
Prepaid Expenses	$11.29M		$3.151M
Receivables	$12.74M	$29.60M	$13.64M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$239.8M	$269.1M	$322.3M
YoY Change	-10.9%	-16.51%	13.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.21M	$56.70M	$49.98M
YoY Change	-14.99%	13.4%	178.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$24.51M	$6.300M	$1.602M
YoY Change	289.34%	293.75%	17.02%
Total Long-Term Assets	$72.72M	$63.00M	$51.59M
YoY Change	15.41%	22.09%	88.85%
TOTAL ASSETS
Total Short-Term Assets	$239.8M	$269.1M	$322.3M
Total Long-Term Assets	$72.72M	$63.00M	$51.59M
Total Assets	$312.5M	$332.1M	$373.9M
YoY Change	-5.91%	-11.18%	20.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.308M	$4.000M	$2.451M
YoY Change	7.57%	60.0%	-38.65%
Accrued Expenses	$27.14M	$33.00M	$38.58M
YoY Change	-18.25%	-14.51%	139.13%
Deferred Revenue	$10.70M
YoY Change	-50.74%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$300.0K
YoY Change			-81.25%
Total Short-Term Liabilities	$45.17M	$59.90M	$49.76M
YoY Change	-24.65%	20.28%	82.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00	$29.30M	$24.90M
YoY Change	-100.0%	17.67%	67.11%
Total Long-Term Liabilities	$0.00	$29.30M	$24.90M
YoY Change	-100.0%	17.67%	63.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.17M	$59.90M	$49.76M
Total Long-Term Liabilities	$0.00	$29.30M	$24.90M
Total Liabilities	$81.87M	$89.30M	$74.65M
YoY Change	-8.27%	19.71%	75.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$642.1M		-$312.3M
YoY Change	30.96%		6.7%
Common Stock	$872.7M		$611.6M
YoY Change	19.03%		8.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$230.6M	$242.9M	$299.2M
YoY Change
Total Liabilities & Shareholders Equity	$312.5M	$332.1M	$373.9M
YoY Change	-5.91%	-11.18%	20.12%

Cashflow Statement

Concept	2019 Q4	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$30.40M	-$171.5M	$105.7M
YoY Change	-31.91%	773.6%	-403.96%
Depreciation, Depletion And Amortization	$2.730M	$9.160M	$1.340M
YoY Change	-9.3%	26.73%	-32.32%
Cash From Operating Activities	-$38.04M	-$153.2M	$111.9M
YoY Change	39.75%	-1163.76%	-494.81%
INVESTING ACTIVITIES
Capital Expenditures	-$1.250M	$24.95M	-$10.75M
YoY Change	76.06%	-15.13%	914.15%
Acquisitions
YoY Change
Other Investing Activities	$8.870M	$81.60M	$19.40M
YoY Change	-80.63%	-23.94%	527.83%
Cash From Investing Activities	$7.620M	$56.64M	$8.640M
YoY Change	-83.09%	-27.26%	325.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$103.3M
YoY Change		201.54%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	290.0K	$105.0M	360.0K
YoY Change	-38.3%	197.02%	-26.53%
NET CHANGE
Cash From Operating Activities	-38.04M	-$153.2M	111.9M
Cash From Investing Activities	7.620M	$56.64M	8.640M
Cash From Financing Activities	290.0K	$105.0M	360.0K
Net Change In Cash	-30.13M	$8.401M	120.9M
YoY Change	-264.47%	-93.42%	-568.23%
FREE CASH FLOW
Cash From Operating Activities	-$38.04M	-$153.2M	$111.9M
Capital Expenditures	-$1.250M	$24.95M	-$10.75M
Free Cash Flow	-$36.79M	-$178.2M	$122.6M
YoY Change	38.78%	1088.08%	-549.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36112
CY2020	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2020	dei	City Area Code CityAreaCode	301
CY2020	dei	Local Phone Number LocalPhoneNumber	251-5172
CY2020	dei	Security12b Title Security12bTitle	Common stock, par value $0.01 per share
CY2020	dei	Trading Symbol TradingSymbol	MGNX
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1500000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56258468	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181131000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126472000	USD
CY2020Q4	us-gaap	Investments Investments	91400000	USD
CY2019Q4	us-gaap	Investments Investments	89284000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23081000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12744000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16982000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11285000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	312594000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	239785000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42225000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48211000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23924000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24505000	USD
CY2020Q4	us-gaap	Assets Assets	378743000	USD
CY2019Q4	us-gaap	Assets Assets	312501000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8031000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4308000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34198000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27139000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3988000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3020000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4456000	USD
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10700000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50673000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45167000	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6926000	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9153000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25260000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27553000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	82859000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	81873000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56244771	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48958763	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	562000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	490000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1067150000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	872204000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	16000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-771821000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-642082000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	295884000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	230628000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	378743000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	312501000	USD
CY2020	us-gaap	Revenues Revenues	104883000	USD
CY2019	us-gaap	Revenues Revenues	64188000	USD
CY2018	us-gaap	Revenues Revenues	60121000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193201000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	190827000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	195309000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42742000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46064000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40500000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	235943000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	241373000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	231327000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-131060000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-177185000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-171206000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1321000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25374000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-247000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-129739000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-151811000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-151811000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-171453000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-171453000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-23000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	19000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	58000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-129762000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-151792000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-171395000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.47
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-3.16
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-4.19
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52442389	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48082728	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40925318	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	299238000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16520000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	103259000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-171453000	USD
CY2018	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	1733000	USD
CY2018	us-gaap	Treasury Stock Retired Par Value Method Amount TreasuryStockRetiredParValueMethodAmount	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	58000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	242877000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19571000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	118657000	USD
CY2019	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	1315000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	19000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-151811000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	230628000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20676000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	170456000	USD
CY2020	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	3886000	USD
CY2020	us-gaap	Treasury Stock Retired Par Value Method Amount TreasuryStockRetiredParValueMethodAmount	0	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-23000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-171453000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11957000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-129739000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	295884000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-129739000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-151811000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12306000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9160000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	260000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1461000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	881000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	20676000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	19571000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	16520000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10337000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16839000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15941000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5697000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4878000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3255000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-581000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1578000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4580000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3723000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	787000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1554000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6994000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6057000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3208000	USD
CY2020	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1324000	USD
CY2019	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	2881000	USD
CY2018	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8472000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8401000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-20869000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	13405000	USD
CY2020	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2019	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2018	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-971000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-111898000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-134270000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-153234000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	223745000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	264399000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	132750000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	221866000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	189330000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	214348000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5906000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4289000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24954000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7785000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-79358000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	56644000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	170456000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	118657000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103259000	USD
CY2020	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	5898000	USD
CY2019	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	1315000	USD
CY2018	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	1992000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2012000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	260000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	174342000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119972000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	104991000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54659000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-93656000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126472000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220128000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	211727000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181131000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126472000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220128000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6408000	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	mgnx	Fair Value Of Warrants Received FairValueOfWarrantsReceived	0	USD
CY2019	mgnx	Fair Value Of Warrants Received FairValueOfWarrantsReceived	0	USD
CY2018	mgnx	Fair Value Of Warrants Received FairValueOfWarrantsReceived	6130000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19300000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</span></div>
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	143403000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	162506000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	52000000.0	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	73200000	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div>
CY2020Q4	us-gaap	Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset	0	USD
CY2018Q4	us-gaap	Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset	0	USD
CY2019Q4	us-gaap	Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset	0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16400000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	27700000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	91407000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	91400000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	89268000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	26000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	89284000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	800000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	3400000	USD
CY2018	us-gaap	Interest Income Other InterestIncomeOther	2300000	USD
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2022000	USD
CY2019Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	187000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	103776000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	97936000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61551000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	49725000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42225000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48211000	USD
CY2020	us-gaap	Depreciation Depreciation	12000000.0	USD
CY2019	us-gaap	Depreciation Depreciation	12300000	USD
CY2018	us-gaap	Depreciation Depreciation	9200000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.097
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.099
CY2019	mgnx	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	renewalOption
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	5900000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	6400000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20200000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	5410000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	5463000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	1083000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	1366000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	770000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	942000	USD
CY2020	us-gaap	Lease Cost LeaseCost	5723000	USD
CY2019	us-gaap	Lease Cost LeaseCost	5887000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6726000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6940000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6796000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5856000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5084000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7764000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	39166000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9918000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	29248000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20676000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19571000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16520000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6706994	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6973272	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.33
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1851327	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.11
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	504445	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.56
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	795523	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	20.72
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7258353	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.48
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	27409000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4660921	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.92
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13906000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	700000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	900000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.57
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	26011000	USD
CY2020	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	504445	shares
CY2019	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	219045	shares
CY2018	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	274362	shares
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5300000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.68
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.98
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.90
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4300000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2900000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5200000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	16700000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	17700000	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	16400000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	27500000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	136086000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	116436000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	37465000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	31110000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	50271000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	35580000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	23409000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	22881000	USD
CY2020Q4	mgnx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	8048000	USD
CY2019Q4	mgnx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	8413000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3132000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	367000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14285000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9123000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	272696000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	223910000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	263403000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	214893000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9293000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9017000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2123000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	438000	USD
CY2020Q4	mgnx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	5316000	USD
CY2019Q4	mgnx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	5547000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1854000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	3032000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9293000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9017000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	mgnx	Operating Loss Carryforwards Not Subject To Limitation OperatingLossCarryforwardsNotSubjectToLimitation	634500000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-27245000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-31880000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-36005000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-8100000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-9524000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-11133000	USD
CY2020	mgnx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount	344000	USD
CY2019	mgnx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount	2004000	USD
CY2018	mgnx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount	-4435000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	14691000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5830000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	8466000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	528000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	301000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	872000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1156000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1206000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	148000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	554000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1889000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	758000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	48510000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	42436000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	60005000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4950000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4318000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3395000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	839000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	637000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	642000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	337000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	5000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	281000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6126000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4950000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4318000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	6100000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4900000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2014	mgnx	Employees Eligible Age To Participate In Benefit Plan EmployeesEligibleAgeToParticipateInBenefitPlan	P21Y
CY2014	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2020	mgnx	Defined Contribution Plan Employees Contribution Vested Percentage DefinedContributionPlanEmployeesContributionVestedPercentage	1
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1400000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1400000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1300000	USD

Files In Submission

Name	View Source	Status
0001125345-21-000035-index-headers.html	Edgar Link	pending
0001125345-21-000035-index.html	Edgar Link	pending
0001125345-21-000035.txt	Edgar Link	pending
0001125345-21-000035-xbrl.zip	Edgar Link	pending
exhibit1015cmcagreement.htm	Edgar Link	pending
exhibit1016incytecommercia.htm	Edgar Link	pending
exhibit1017eversanaagreeme.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
incytelogo1a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20201231.htm	Edgar Link	pending
mgnx-20201231.xsd	Edgar Link	pending
mgnx-20201231_cal.xml	Edgar Link	unprocessable
mgnx-20201231_def.xml	Edgar Link	unprocessable
mgnx-20201231_g1.jpg	Edgar Link	pending
mgnx-20201231_g2.jpg	Edgar Link	pending
mgnx-20201231_g3.jpg	Edgar Link	pending
mgnx-20201231_g4.jpg	Edgar Link	pending
mgnx-20201231_g5.jpg	Edgar Link	pending
mgnx-20201231_g6.jpg	Edgar Link	pending
mgnx-20201231_htm.xml	Edgar Link	completed
mgnx-20201231_lab.xml	Edgar Link	unprocessable
mgnx-20201231_pre.xml	Edgar Link	unprocessable
mgnxexhibit23-1202010xk.htm	Edgar Link	pending
mgnxexhibit31-1202010xk.htm	Edgar Link	pending
mgnxexhibit31-2202010xk.htm	Edgar Link	pending
mgnxexhibit32-1202010xk.htm	Edgar Link	pending
mgnxexhibit32-2202010xk.htm	Edgar Link	pending
mgnxexhibit4-2202010xk.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2019 Q4 Form 10-K Financial Statement

#000112534521000035 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2019 Q4 Form 10-K Financial Statement

#000112534521000035 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx